Legend Biotech Corp
NASDAQ:LEGN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
37.42
69.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Legend Biotech Corp
Balance Sheet
Balance Sheet Decomposition
Legend Biotech Corp
| Current Assets | 1.4B |
| Cash & Short-Term Investments | 1.2B |
| Receivables | 104m |
| Other Current Assets | 33.1m |
| Non-Current Assets | 385.8m |
| PP&E | 203.5m |
| Intangibles | 2.5m |
| Other Non-Current Assets | 179.8m |
| Current Liabilities | 270.9m |
| Accounts Payable | 26.9m |
| Accrued Liabilities | 139.3m |
| Other Current Liabilities | 104.7m |
| Non-Current Liabilities | 348.8m |
| Long-Term Debt | 342.2m |
| Other Non-Current Liabilities | 6.6m |
Balance Sheet
Legend Biotech Corp
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
2
|
210
|
83
|
456
|
689
|
786
|
1 278
|
|
| Cash Equivalents |
2
|
210
|
83
|
456
|
689
|
786
|
1 278
|
|
| Short-Term Investments |
0
|
6
|
76
|
50
|
195
|
241
|
31
|
|
| Total Receivables |
228
|
26
|
30
|
83
|
58
|
46
|
157
|
|
| Accounts Receivables |
228
|
26
|
30
|
75
|
50
|
0
|
100
|
|
| Other Receivables |
0
|
0
|
0
|
8
|
8
|
45
|
57
|
|
| Inventory |
0
|
1
|
1
|
2
|
2
|
10
|
19
|
|
| Other Current Assets |
1
|
83
|
22
|
4
|
6
|
16
|
12
|
|
| Total Current Assets |
231
|
327
|
212
|
594
|
950
|
1 099
|
1 498
|
|
| PP&E Net |
3
|
32
|
73
|
112
|
141
|
161
|
189
|
|
| PP&E Gross |
3
|
32
|
0
|
112
|
141
|
161
|
189
|
|
| Accumulated Depreciation |
0
|
1
|
0
|
11
|
17
|
25
|
35
|
|
| Intangible Assets |
0
|
0
|
1
|
3
|
5
|
3
|
4
|
|
| Note Receivable |
0
|
1
|
1
|
0
|
2
|
1
|
1
|
|
| Other Long-Term Assets |
5
|
69
|
6
|
13
|
22
|
67
|
157
|
|
| Total Assets |
239
N/A
|
429
+80%
|
293
-32%
|
722
+147%
|
1 120
+55%
|
1 331
+19%
|
1 849
+39%
|
|
| Liabilities | ||||||||
| Accounts Payable |
4
|
8
|
81
|
5
|
7
|
33
|
153
|
|
| Accrued Liabilities |
8
|
34
|
0
|
71
|
101
|
149
|
102
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
1
|
2
|
1
|
4
|
3
|
|
| Other Current Liabilities |
40
|
117
|
13
|
38
|
121
|
112
|
91
|
|
| Total Current Liabilities |
52
|
159
|
94
|
116
|
229
|
298
|
216
|
|
| Long-Term Debt |
0
|
4
|
5
|
2
|
122
|
281
|
325
|
|
| Deferred Income Tax |
0
|
0
|
42
|
4
|
0
|
0
|
0
|
|
| Other Liabilities |
174
|
257
|
0
|
3
|
2
|
8
|
55
|
|
| Total Liabilities |
227
N/A
|
420
+86%
|
141
-66%
|
124
-12%
|
354
+184%
|
587
+66%
|
597
+2%
|
|
| Equity | ||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
12
|
9
|
151
|
598
|
766
|
744
|
1 251
|
|
| Total Equity |
12
N/A
|
9
-30%
|
151
+1 659%
|
598
+295%
|
766
+28%
|
744
-3%
|
1 251
+68%
|
|
| Total Liabilities & Equity |
239
N/A
|
429
+80%
|
293
-32%
|
722
+147%
|
1 120
+55%
|
1 331
+19%
|
1 849
+39%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
259
|
259
|
0
|
0
|
0
|
330
|
364
|
|
You don't have any saved screeners yet
